This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why the Earnings Surprise Streak Could Continue for Humana (HUM)
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WellCare Health, agilon health to Provide Value-Based Care
by Zacks Equity Research
WellCare Health (WCG) purchases agilon health to provide enriched patient care in Texas.
Employer Sponsored Health Insurance Premiums Jump: 4 Picks
by Ritujay Ghosh
An increasing number of memberships, with unemployment rate hitting a record low, have been one of the prime factors behind the top-line growth of the health insurance sector.
4 Health Insurance Stocks Poised for Earnings Beat in Q3
by Sapna Bagaria
Higher enrollment, premium increase, cost management and share buyback should aid health insurers' earnings in the third quarter, partly offset by higher operating costs.
Fitbit Partners With Humana, Unviels Fitbit Care Platform
by Zacks Equity Research
Fitbit (FIT) unveils a new enterprise health care platform and also expands its partnership with Humana in a bid to expand its share in the healthcare market.
Humana (HUM) Expands Pact With Fitbit to Rein in Claim Cost
by Zacks Equity Research
Humana (HUM) expands its wellness program to manage claim cost and members' health.
WellCare (WCG) Buys Meridian, Boosts Medicaid Membership
by Zacks Equity Research
WellCare (WCG) acquires Meridian to drive portfolio and increase Medicaid membership.
UnitedHealth's Optum to Jointly Acquire Sound Physicians
by Zacks Equity Research
UnitedHealth's (UNH) unit to buy Sound Physicians for portfolio boost.
Humana (HUM) Launches Center for Digital Health Enhancement
by Zacks Equity Research
Humana (HUM) starts a center to boost digital capabilities for supporting its integrated care delivery model.
Humana (HUM) Hits 52 Week High: Will the Rally Continue?
by Zacks Equity Research
Humana (HUM) reaches 52-week high in the trading session of Aug 24, backed by strong-second quarter results and initiatives for portfolio boost.
Humana Inks Deal to Offer Value-Based Care to MA Members
by Zacks Equity Research
Humana (HUM) signs a contract with The University of Chicago Medicine to provide its Medicare advantage members with better healthcare services.
5 Solid Reasons to Invest in Anthem for Portfolio Boost
by Zacks Equity Research
Riding high on growing membership and a robust capital position, Anthem (ANTM) holds great prospects to reap profitable returns for investors.
Tenet (THC) Closes the Divestment of Aspen Healthcare in UK
by Zacks Equity Research
Tenet (THC) completes the pending divestiture of Aspen Healthcare to NMC Healthcare in the United Kingdom.
Anthem Ties Up With Walmart to Better Serve Medicare Members
by Zacks Equity Research
Anthem (ANTM) teams up with Walmart to provide medical supplies across its counter.
Aetna Launches Scheme for Better Patient Care Amenities
by Zacks Equity Research
Aetna (AET) proposes a new regional plan to serve employers better.
Centene (CNC) Reaches 52-Week High on Solid 2Q18 Performance
by Zacks Equity Research
Riding high on five main factors, Centene's (CNC) shares scale a 52-week high on Aug 10, 2018.
Humana (HUM): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Humana (HUM) is seeing solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Humana Completes Sale of KMG Subsidiary to HC2 Holdings
by Zacks Equity Research
Humana (HUM) divests its long-term care business to focus on core operations.
WellCare Health Sees Moody's Rating Action, Outlook Stable
by Zacks Equity Research
WellCare Health (WCG) and unit get Moody's ratings while the outlook changes to stable.
Q2 Scorecard & Research Reports for Gilead, American Tower & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), American Tower (AMT) and Chubb (CB).
Humana's (HUM) Q2 Earnings Beat Estimates, Ups Guidance
by Zacks Equity Research
Humana's (HUM) second quarter earnings reflect growth on the back of higher revenues, view raised.
Humana (HUM) Surpasses on Q2 Earnings, Raises EPS Guidance
by Zacks Equity Research
Humana's (HUM) Q2 earnings register growth on the back of Medicare Advantage enrollment and solid strategies. The company also lifts its EPS outlook.
WellCare Health Plans (WCG) Jumps: Stock Rises 7.3%
by Zacks Equity Research
WellCare Health Plans (WCG) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Humana (HUM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 4.49% and 0.71%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM
by Zacks Equity Research
Solid R&D prospects likely to drive the healthcare industry in Q2 earnings.